Researchers preparing to conduct a Phase 3 clinical trial of the mesothelioma drug nintedanib have officially enrolled their first mesothelioma patient. Eventually, close to 400 others will be signed up. The researchers say they intend to use this study to see how well nintedanib works for patients with unresectable malignant pleural mesothelioma. They said the